Surprising SanBio/Sumitomo Stroke Stumble Slams Stocks
Mesenchymal stem cell-based therapy's missed Phase IIb endpoint in stroke prompts both an assessment of future development plans and a precipitous fall in developers' stocks.
You may also be interested in...
Keeping Track: A Duo Of RTOR Approvals, Thumbs Up For First Oral GLP-1 Treatment, And First Ebola Vaccine Nears US Market
The latest drug development news and highlights from our US FDA Performance Tracker.
Facing looming expiries for its top product, Japan’s Sumitomo Dainippon is planning to acquire multiple "vant" companies and their portfolios of clinical stage assets from Roivant, in a move to address mid-term challenges to revenues and following recent late-stage development failures.
Australian venture with Phase II-ready cell therapy in sights of Sumitomo Dainippon as Japanese firm looks to build regenerative medicine interests and pipeline ahead of major expiry.